Interestingly, ruxolitinib did not show comparable effects on expression of these antigens on MPN NSC, which is most probably due to the much weaker effects of this drug on JAK2 and JAK2V617F compared to fedratinib. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.